Agreements and pacts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Agreements and pacts
The latest pacts from the pharmaceutical supply chain

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

Mumbai (Aug. 6)Novartis (Basel, Switzerland) reported that the High Court in Chennai dismissed its writ petition challenging the constitutionality of Section 3(d), and deferred to the World Trade Organization (WTO) forum to resolve the TRIPS compliance question. India denied Novartis's patent application for the anticancer drug "Gleevec/Glivec" (imatinib) in 2006.

"We disagree with this ruling, however we likely will not appeal to the Supreme Court. We await the full decision to better understand the Court's position," said Ranjit Shahani, vice-chairman and managing director with Novartis India Limited, in a company release. "Our actions advanced this essential debate in India; now local and international leaders in both industry and academia recognize the inadequacies of Section 3(d) and are raising serious concerns about the deficiencies of the Indian patent system."

Novartis originally filed the appeal in India because the Indian patent office rejected the Gleevec/Glivec patent application. "Because the patent rejection was based on Section 3(d), we challenged this specific provision in India," said Shahani. "We had hoped to resolve this question on Section 3(d) locally in order to receive a patent for Glivec."

Novartis says still at issue is why a patent for Glivec was denied in India in 2006. The Glivec patent appeal will be decided separately by the newly-operational Intellectual Property Appellate Board (IPAB). Novartis also is petitioning the High Court for a new technical member because the current technical member is the former Controller General of the Indian Patent Office, responsible for the original rejection of the Glivec patent.

"We expect the appellate board to conduct an independent and impartial review of our appeal and ensure transparency of the decision-making process," said Shahani in a company release.

London (Aug. 2)AstraZeneca selected Kuehne + Nagel (Jersey City, NJ) to handle part of its exports of temperature-sensitive pharmaceutical products from Europe to the rest of the world. Under the agreement, Kuehne + Nagel will supply a complete solution for the transportation by air and sea of products indicated for therapeutic categories, including oncology and anesthetics, as well as active pharmaceutical ingredients.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here